Suranganie Dharmawardhane
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| rac GTP-Binding Proteins | 9 | 2024 | 25 | 3.700 |
Why?
|
| cdc42 GTP-Binding Protein | 6 | 2021 | 24 | 2.700 |
Why?
|
| Breast Neoplasms | 17 | 2021 | 1679 | 2.400 |
Why?
|
| rac1 GTP-Binding Protein | 6 | 2025 | 47 | 2.110 |
Why?
|
| Stilbenes | 8 | 2016 | 44 | 1.850 |
Why?
|
| Carbazoles | 7 | 2021 | 46 | 1.760 |
Why?
|
| Antineoplastic Agents | 9 | 2019 | 979 | 1.670 |
Why?
|
| Pyrimidines | 7 | 2021 | 130 | 1.600 |
Why?
|
| Cell Line, Tumor | 22 | 2025 | 2598 | 1.160 |
Why?
|
| Vitis | 4 | 2016 | 37 | 1.150 |
Why?
|
| Isoflavones | 5 | 2021 | 132 | 1.000 |
Why?
|
| Neoplasm Metastasis | 7 | 2017 | 233 | 0.940 |
Why?
|
| Eukaryotic Initiation Factor-4G | 3 | 2015 | 14 | 0.920 |
Why?
|
| Catechin | 3 | 2016 | 38 | 0.880 |
Why?
|
| Quercetin | 3 | 2016 | 46 | 0.870 |
Why?
|
| Paclitaxel | 1 | 2024 | 64 | 0.860 |
Why?
|
| Genistein | 3 | 2016 | 43 | 0.820 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2025 | 933 | 0.820 |
Why?
|
| Cell Proliferation | 14 | 2025 | 1420 | 0.810 |
Why?
|
| GTP-Binding Proteins | 1 | 2022 | 58 | 0.770 |
Why?
|
| Mice | 16 | 2024 | 6490 | 0.710 |
Why?
|
| Cell Movement | 8 | 2025 | 640 | 0.680 |
Why?
|
| Enzyme Inhibitors | 2 | 2013 | 457 | 0.670 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 159 | 0.640 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2015 | 62 | 0.620 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 209 | 0.610 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 290 | 0.580 |
Why?
|
| Saccharomycetales | 1 | 2018 | 8 | 0.580 |
Why?
|
| Cell Polarity | 1 | 2018 | 55 | 0.570 |
Why?
|
| Female | 25 | 2024 | 24018 | 0.550 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2016 | 297 | 0.540 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2009 | 69 | 0.540 |
Why?
|
| Mice, Nude | 7 | 2016 | 403 | 0.540 |
Why?
|
| Animals | 20 | 2024 | 16695 | 0.530 |
Why?
|
| Cell Survival | 8 | 2017 | 934 | 0.500 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 137 | 0.490 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2016 | 134 | 0.490 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2015 | 230 | 0.480 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2015 | 458 | 0.480 |
Why?
|
| Protein Biosynthesis | 2 | 2015 | 136 | 0.470 |
Why?
|
| Receptors, Estrogen | 3 | 2015 | 177 | 0.470 |
Why?
|
| Actins | 2 | 2007 | 162 | 0.460 |
Why?
|
| Breast | 1 | 2016 | 139 | 0.460 |
Why?
|
| Signal Transduction | 4 | 2018 | 2111 | 0.450 |
Why?
|
| Mice, SCID | 4 | 2021 | 158 | 0.450 |
Why?
|
| Drug Design | 2 | 2013 | 183 | 0.450 |
Why?
|
| Humans | 32 | 2025 | 42163 | 0.440 |
Why?
|
| Estradiol | 3 | 2007 | 269 | 0.430 |
Why?
|
| Phytoestrogens | 2 | 2012 | 40 | 0.400 |
Why?
|
| Apoptosis | 5 | 2024 | 1541 | 0.380 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2013 | 65 | 0.370 |
Why?
|
| Quinazolines | 1 | 2012 | 37 | 0.360 |
Why?
|
| Reishi | 1 | 2011 | 10 | 0.360 |
Why?
|
| Up-Regulation | 3 | 2021 | 534 | 0.340 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2024 | 339 | 0.330 |
Why?
|
| MicroRNAs | 1 | 2016 | 501 | 0.320 |
Why?
|
| Plant Extracts | 1 | 2013 | 303 | 0.310 |
Why?
|
| Cytoskeleton | 2 | 2007 | 111 | 0.310 |
Why?
|
| p21-Activated Kinases | 3 | 2013 | 18 | 0.310 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2009 | 21 | 0.300 |
Why?
|
| Neoplasms | 2 | 2018 | 1341 | 0.290 |
Why?
|
| Bone Neoplasms | 1 | 2009 | 48 | 0.290 |
Why?
|
| Fluorescent Dyes | 2 | 2006 | 182 | 0.290 |
Why?
|
| Aminoquinolines | 3 | 2013 | 17 | 0.280 |
Why?
|
| Proto-Oncogene Proteins c-vav | 2 | 2025 | 8 | 0.260 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2007 | 18 | 0.260 |
Why?
|
| Luminescent Agents | 1 | 2006 | 4 | 0.260 |
Why?
|
| Luminescent Proteins | 1 | 2006 | 65 | 0.250 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2006 | 184 | 0.240 |
Why?
|
| Estrogens | 1 | 2007 | 202 | 0.230 |
Why?
|
| Cell Division | 2 | 2022 | 314 | 0.230 |
Why?
|
| Focal Adhesions | 1 | 2005 | 16 | 0.230 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 287 | 0.220 |
Why?
|
| Mice, Inbred BALB C | 2 | 2024 | 686 | 0.210 |
Why?
|
| Carbon | 1 | 2024 | 127 | 0.200 |
Why?
|
| Down-Regulation | 2 | 2016 | 452 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 1112 | 0.200 |
Why?
|
| Molecular Structure | 4 | 2019 | 560 | 0.200 |
Why?
|
| Neoplasm Invasiveness | 3 | 2011 | 284 | 0.200 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2022 | 33 | 0.200 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2021 | 147 | 0.190 |
Why?
|
| Neoplasm Transplantation | 2 | 2012 | 129 | 0.180 |
Why?
|
| Cell Cycle | 2 | 2016 | 348 | 0.180 |
Why?
|
| Spheroids, Cellular | 1 | 2021 | 37 | 0.170 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2019 | 39 | 0.170 |
Why?
|
| Point Mutation | 1 | 2021 | 98 | 0.170 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 1554 | 0.170 |
Why?
|
| Blotting, Western | 3 | 2014 | 884 | 0.170 |
Why?
|
| Estrogen Receptor beta | 3 | 2013 | 39 | 0.170 |
Why?
|
| Tumor Cells, Cultured | 5 | 2014 | 506 | 0.160 |
Why?
|
| Receptor, erbB-2 | 1 | 2021 | 149 | 0.160 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2019 | 14 | 0.160 |
Why?
|
| Estrogen Receptor alpha | 3 | 2013 | 120 | 0.160 |
Why?
|
| MAP Kinase Signaling System | 1 | 2021 | 189 | 0.160 |
Why?
|
| Disease Progression | 3 | 2019 | 661 | 0.150 |
Why?
|
| Adipocytes | 1 | 2019 | 58 | 0.150 |
Why?
|
| Cell Communication | 1 | 2019 | 110 | 0.150 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2012 | 293 | 0.150 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2011 | 196 | 0.140 |
Why?
|
| Indoles | 1 | 2019 | 178 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 602 | 0.120 |
Why?
|
| Dietary Supplements | 2 | 2021 | 208 | 0.120 |
Why?
|
| Pseudopodia | 2 | 2007 | 15 | 0.120 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2016 | 64 | 0.120 |
Why?
|
| Epidermal Growth Factor | 2 | 2007 | 69 | 0.120 |
Why?
|
| Prostatic Neoplasms | 1 | 2025 | 1068 | 0.120 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 59 | 0.120 |
Why?
|
| bcl-Associated Death Protein | 1 | 2014 | 7 | 0.110 |
Why?
|
| Protein Binding | 1 | 2018 | 1076 | 0.110 |
Why?
|
| Pregnenolone | 1 | 2014 | 17 | 0.110 |
Why?
|
| Linear Models | 1 | 2015 | 311 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2013 | 14 | 0.100 |
Why?
|
| Hela Cells | 1 | 2015 | 370 | 0.100 |
Why?
|
| Organometallic Compounds | 1 | 2014 | 72 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2013 | 36 | 0.100 |
Why?
|
| Mice, Hairless | 1 | 2013 | 7 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 649 | 0.100 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2012 | 17 | 0.100 |
Why?
|
| RNA, Neoplasm | 1 | 2012 | 25 | 0.100 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 98 | 0.100 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2012 | 27 | 0.090 |
Why?
|
| Adenylate Kinase | 1 | 2012 | 14 | 0.090 |
Why?
|
| Catenins | 1 | 2011 | 5 | 0.090 |
Why?
|
| bcl-X Protein | 1 | 2011 | 27 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 52 | 0.090 |
Why?
|
| Enzyme Activation | 3 | 2013 | 462 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2014 | 1265 | 0.090 |
Why?
|
| Sirolimus | 1 | 2012 | 70 | 0.090 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2011 | 76 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 1058 | 0.090 |
Why?
|
| Caspase 3 | 1 | 2012 | 226 | 0.090 |
Why?
|
| Cadherins | 1 | 2011 | 102 | 0.090 |
Why?
|
| Binding Sites | 1 | 2012 | 670 | 0.080 |
Why?
|
| Postmenopause | 2 | 2021 | 139 | 0.080 |
Why?
|
| Obesity | 1 | 2017 | 1131 | 0.080 |
Why?
|
| Saponins | 1 | 2007 | 7 | 0.070 |
Why?
|
| Asteraceae | 1 | 2007 | 4 | 0.070 |
Why?
|
| Focal Adhesion Kinase 1 | 2 | 2005 | 20 | 0.070 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 2 | 2005 | 21 | 0.070 |
Why?
|
| Triterpenes | 1 | 2007 | 18 | 0.070 |
Why?
|
| Genes, Dominant | 1 | 2007 | 20 | 0.070 |
Why?
|
| Optical Fibers | 1 | 2006 | 8 | 0.070 |
Why?
|
| Fiber Optic Technology | 1 | 2006 | 11 | 0.070 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2007 | 25 | 0.060 |
Why?
|
| Optics and Photonics | 1 | 2007 | 43 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2005 | 139 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2007 | 53 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 1066 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2009 | 355 | 0.060 |
Why?
|
| Transfection | 1 | 2007 | 526 | 0.060 |
Why?
|
| Microscopy, Confocal | 2 | 2004 | 223 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2005 | 62 | 0.060 |
Why?
|
| Inflammation | 2 | 2019 | 729 | 0.050 |
Why?
|
| Phenotype | 1 | 2005 | 774 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2005 | 400 | 0.050 |
Why?
|
| Flavonoids | 1 | 2002 | 94 | 0.050 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2002 | 29 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 683 | 0.050 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2002 | 89 | 0.040 |
Why?
|
| Culture Media, Conditioned | 1 | 2019 | 49 | 0.040 |
Why?
|
| 3T3-L1 Cells | 1 | 2019 | 17 | 0.040 |
Why?
|
| Culture Media | 1 | 2019 | 96 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2014 | 411 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2019 | 491 | 0.030 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2017 | 12 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2014 | 973 | 0.030 |
Why?
|
| STAT Transcription Factors | 1 | 2014 | 12 | 0.030 |
Why?
|
| Reference Standards | 1 | 2014 | 55 | 0.030 |
Why?
|
| Calibration | 1 | 2014 | 62 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 111 | 0.030 |
Why?
|
| beta Catenin | 1 | 2014 | 75 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2014 | 84 | 0.030 |
Why?
|
| Mastocytosis | 1 | 2013 | 3 | 0.030 |
Why?
|
| Mice, Inbred C3H | 1 | 2013 | 80 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2014 | 189 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 456 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2013 | 88 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 3077 | 0.020 |
Why?
|
| Kidney | 1 | 2014 | 363 | 0.020 |
Why?
|
| Liver | 1 | 2014 | 503 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 1804 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2007 | 140 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2007 | 300 | 0.020 |
Why?
|
| Middle Aged | 1 | 2021 | 11819 | 0.020 |
Why?
|
| Contrast Media | 1 | 2007 | 101 | 0.020 |
Why?
|
| Male | 1 | 2025 | 22779 | 0.010 |
Why?
|
| Adult | 1 | 2021 | 13458 | 0.010 |
Why?
|
| Streptavidin | 1 | 2004 | 6 | 0.010 |
Why?
|
| Fluorometry | 1 | 2004 | 17 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 2004 | 30 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2004 | 106 | 0.010 |
Why?
|
| Mouth Neoplasms | 1 | 2004 | 60 | 0.010 |
Why?
|
| Biopsy | 1 | 2004 | 176 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 2004 | 83 | 0.010 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2002 | 21 | 0.010 |
Why?
|
| Plant Preparations | 1 | 2002 | 25 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2002 | 255 | 0.010 |
Why?
|